29 February is Rare Disease Day

29 February is Rare Disease Day

This year, Rare Diseases Day (RDD) falls on the rarest day of all in 2024 – 29 February! The event, held annually, aims to raise awareness of rare diseases and their impact on those living with them, their families, and caregivers.

At Janssen, we are committed to this goal, and are working to drive change for the 300 million people worldwide (and approximately 30 million in Europe) who are living with one of the 6,000-plus rare diseases. Our participation in awareness events, such as RDD, is an integral part of this.

We make strides by focused research and development programs to ultimately bring new, groundbreaking medicines to those affected by rare diseases. With our expertise in therapeutic areas like Pulmonary Hypertension, Retina, Immunology, Oncology and Neuroscience, we leverage scientific and operational knowledge to make a difference. Collaborating globally with partners and utilizing innovative tools, we are invested in improving health outcomes for individuals impacted by rare diseases.

At Janssen, we understand the importance of time for those affected by rare diseases. Patients shouldn't have to wait endlessly for diagnosis and treatment. That's why we focus on areas where we have the potential to make a substantial impact, including rare diseases. We tirelessly advance the science and chase breakthroughs in conditions like pulmonary arterial hypertension (PAH), AL amyloidosis, myasthenia gravis, rare inherited retinal diseases, rare maternal-fetal diseases, and rare blood disorders and cancers.

Our work at Janssen is fueled by the vision of a future where disease is a thing of the past. We are dedicated to finding lasting solutions and never cease in our pursuit.

Visit our dedicated pages

See examples of how we’re raising awareness for people living with rare disease.

Pulmonary Hypertension
Inherited retinal diseases

Rare diseases in numbers

 

 

* Image source of header and banner: Rare Disease Day website. https://www.rarediseaseday.org

References

Myasthenia Gravis Foundation of America (MGFA). A Manual for the Healthcare Provider. Available at: https://myasthenia.org/Portals/0/Provider%20Manual_ibook%20version.pdf Last accessed: June 2024.
National Institute of Neurological Disorders and Stroke (NINDS). Myasthenia Gravis. Available at: https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis Last accessed: June 2024.
Dewilde S, et al. People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies. Adv Ther. Vol 40, 4377–4394 (2023). Available at: https://doi.org/10.1007/s12325-023-02604-z Last accessed: June 2024.
Mahic, et al. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disorders (2023). Available at: https://doi.org/10.1177/17562864221150327 Last accessed: June 2024.
Daum P et al. Perioperative management of myasthenia gravis. BJA Education (2021) 21(11): 414e419
John Hopkins Medicine. Myasthenia Gravis. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/myasthenia-gravis Last accessed: June 2024.
Mishra A, et al. Myasthenia Gravis: A Systematic Review. Cureus (2023) 15(12): e50017. DOI 10.7759/cureus.50017.
Luo H, Xie S, Ma C, Zhang W, Tschöpe C, Fa X, Cheng J, Cao J. Correlation Between Thymus Radiology and Myasthenia Gravis in Clinical Practice. Front Neurol. 2019 Jan 15;9:1173. doi: 10.3389/fneur.2018.01173. PMID: 30697185; PMCID: PMC6340958.
Chen J, Tian D-C, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. The Lancet Regional Health - Western Pacific. 2020;5(100063). https://doi.org/10.1016/j.lanwpc.2020.100063.
Lazaridis K, et al. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020 Feb 14;11:212. doi: 10.3389/fimmu.2020; 00212. Last accessed: June 2024.
Myasthenia Gravis Foundation of America (MGFA). Seronegative MG Resource Center. Available at: https://myasthenia.org/Newly-Diagnosed/Seronegative-MG-Resource-Center Last accessed: June 2024.
Jackson et al. Understanding the symptom burden and impact of myasthenia gravis from the patient’s perspective: A qualitative study. Neurology and Therapy. 2022;12:1; 107–128. Available at: https://doi.org/10.1007/s40120-022-00408-x.
Myasthenia Gravis Foundation of America (MGFA). Myasthenia Gravis Clinical Overview. Available at: https://myasthenia.org/Professionals/Clinical-Overview-of-MG#DIAGNOSTIC. Last accessed: June 2024
NHS. Myasthenia Gravis. Available at: https://www.nhs.uk/conditions/myasthenia-gravis/ Last accessed: June 2024.
NHS. Diagnosis Myasthenia Gravis. Available at: https://www.nhs.uk/conditions/myasthenia-gravis/diagnosis/ Last accessed: June 2024.